291.00p+15.00 (+5.43%)23 Apr 2024, 09:48
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo

Hutchmed (China) Limited Market & Company News

22.04.2024 09:30HCMVesting of Awards Under the LTIPRNS
08.04.2024 09:30HCM2023 Annual Report and Notice of AGMRNS
05.04.2024 09:30HCMData to be Presented at AACR Congress 2024Reach
02.04.2024 10:32HCMHutchmed endometrial cancer treatment application accepted for reviewAlliance
02.04.2024 07:00HCMHUTCHMED and Innovent Announce NDA AcceptanceReach
28.03.2024 11:08HCMHutchmed lung cancer treatment accepted for review in ChinaAlliance
28.03.2024 07:00HCMSavolitinib sNDA Accepted in ChinaReach
22.03.2024 10:09HCMHutchmed begins registration stage for sovleplenib phase 2/3 trialAlliance
22.03.2024 07:00HCMInitiation of Registration Stage of P2/3 TrialReach
14.03.2024 09:00HCMLTIP and Share Option SchemeRNS
05.03.2024 08:30HCMVesting of awards under the LTIPRNS
28.02.2024 17:31TRIG, AIQ, CRVEARNINGS: Hutchmed revenue surges, Craven House's loss widensAlliance
28.02.2024 12:45HCMPublication of Form 20-FReach
28.02.2024 11:30HCM2023 Full Year Results and Business UpdatesRNS
21.02.2024 15:14STJ, RHIM, TRIGUK earnings, trading statements calendar - next 7 daysAlliance
07.02.2024 09:50HCMHutchmed hails fruquintinib trial results for gastric cancer treatmentAlliance
07.02.2024 07:00HCMPresentation of Phase III Data on FruquintinibReach
02.02.2024 09:52HCMHutchmed says Inmagene exercises option to licence drug candidatesAlliance
30.01.2024 09:20HCMHutchmed celebrates cancer drug approval in hometown of Hong KongAlliance
30.01.2024 07:12HCMHUTCHMED Receives Marketing Approval in Hong KongReach
11.01.2024 10:17HCMTOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureauAlliance
11.01.2024 07:00HCMSovleplenib NDA Granted Priority Review in ChinaReach
29.12.2023 08:30HCMTotal Voting RightsRNS
29.12.2023 08:30HCMBlocklisting Six Monthly ReturnRNS
21.12.2023 11:36HCMIN BRIEF: Hutchmed China renews deals with "substantial" shareholdersAlliance
21.12.2023 10:00HCMOverseas Regulatory AnnouncementRNS
13.12.2023 13:56HCMHutchmed completes enrolment for fruquintinib trial Alliance
13.12.2023 07:00HCMInclusion in National Reimbursement Drug ListReach
13.12.2023 07:00HCMCompleted Enrollment of Phase II/III TrialReach
07.12.2023 10:04HCMOverseas Regulatory AnnouncementRNS
01.12.2023 07:00HCMClinical Data to be Presented at CongressesReach
30.11.2023 08:30HCMTotal Voting RightsRNS
09.11.2023 12:16HCMHutchmed hails Takeda's fruquintinib approval from US for cancer formAlliance
09.11.2023 07:00HCMU.S. FDA Approval of FRUZAQLA™ (fruquintinib)RNS
24.10.2023 09:30HCMVesting of awards under the LTIPRNS
16.10.2023 09:30HCMClinical Data to be Presented at ESMO 2023Reach
29.09.2023 10:12HCMHutchmed notes Takeda submits fruquintinib drug application in JapanAlliance
29.09.2023 09:30HCMNDA Submission for Fruquintinib in JapanReach
29.09.2023 09:30HCMTotal Voting RightsRNS
14.09.2023 09:30HCMDirector’s Share DealingRNS
12.09.2023 10:26HCMIN BRIEF: Hutchmed China finalises patient enrolment for TazemetostatAlliance
12.09.2023 09:30HCMPhase IIIb Savolitinib Results at WCLC 2023Reach
12.09.2023 07:00HCMPatient Enrollment Completed for Bridging StudyReach
31.08.2023 09:30HCMTotal Voting RightsRNS
29.08.2023 09:30HCMIN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tagAlliance
29.08.2023 07:00HCMBTD in China for Savolitinib for Gastric CancerReach
21.08.2023 08:46HCMHutchmed China hails trial on sovleplenib meeting primary endpointAlliance
21.08.2023 07:00HCMSovleplenib Phase 3 Study Meets Primary EndpointRNS
07.08.2023 09:30HCMExercise of Share Options by a DirectorRNS
31.07.2023 12:47HCMHutchmed swings to profit after "sharpening goals and priorities"Alliance
31.07.2023 12:00HCMInterim Results and Business UpdatesRNS
24.07.2023 15:46SXS, QTX, PODPUK earnings, trading statements calendar - next 7 daysAlliance
20.07.2023 14:14HCMIN BRIEF: Hutchmed progresses fruquintinib designation and testingAlliance
20.07.2023 07:00HCMBreakthrough Therapy Designation for FruquintinibReach
13.07.2023 09:30HCMChanges to Board and Technical CommitteeRNS
10.07.2023 08:53HCMIN BRIEF: Hutchmed starts study for tumour treatment in China Alliance
10.07.2023 07:00HCMPhase 1 Study of HMPL-415 InitiatedReach
29.06.2023 09:30HCMBlocklisting Six Monthly ReturnRNS
26.06.2023 09:30HCMHUTCHMED to Announce 2023 Half-Year ResultsRNS
16.06.2023 08:51HCMHutchmed, Takeda Fresco-2 study published in The Lancet Alliance
16.06.2023 07:00HCMPhase III FRESCO-2 Results in The LancetRNS
15.06.2023 16:51HCMIN BRIEF: Hutchmed and Takeda get Europe marketing backing for drugAlliance
15.06.2023 15:39HCMMAA of Fruquintinib Validated by the EMARNS
09.06.2023 10:30HCMHUTCHMED Highlights Presentations at EHA and ICMLReach
06.06.2023 10:00HCMLTIP and Share Option SchemeRNS
31.05.2023 09:30HCMTotal Voting RightsRNS
26.05.2023 08:56HCMHutchmed China celebrates FDA review, teases new data at ASCO meetingAlliance
26.05.2023 07:00HCMFruquintinib NDA Granted Priority Review by FDARNS
26.05.2023 07:00HCMHUTCHMED Highlights Presentations at ASCO 2023Reach
17.05.2023 09:30HCMStandard form for notification of major holdingsRNS
12.05.2023 13:15HCMAnnual General Meeting Poll ResultsRNS
12.05.2023 09:30HCMBoard of Directors and Board Committee MembershipRNS
10.05.2023 09:30HCMAppointment of Independent NEDRNS
05.05.2023 15:57WPM, ITIM, HCMUK shareholder meetings calendar - next 7 daysAlliance
28.04.2023 09:30HCMTotal Voting RightsRNS
Showing 1 to 75 of 254